SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
33.00    0.00 (0.00%)
Bid:
32.00
Ask:
34.00
Spread: 2.00 (6.25%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Goliath Development Progress

6 Mar 2025 07:00

RNS Number : 5421Z
Ilika plc
06 March 2025
 

6 March 2025

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Goliath Development Progress

 

Significant development milestone achieved at conclusion of collaboration programme

 

Ilika (AIM: IKA), the UK pioneer in solid-state battery technology, announces it has successfully prototyped a 50Ah Goliath electric vehicle (EV) battery, which is a key targeted outcome of the Faraday Battery Challenge HISTORY programme. The 50Ah prototype is the capacity of battery Ilika will now optimise for its minimum viable product for EVs. The battery is expected to reduce costs, increase the range of EVs and reduce their charging time.

 

This successful prototype build follows the recently announced demonstration of manufacturing in a giga-scale factory setting, using industry standard equipment at the UK Battery Industrialisation Centre, marking the latest step towards commercialisation. It builds on the progress made in 2024 which included the start of commercial testing, shipping of the first batch of prototype Goliath batteries to customers, and the release of validated safety data.

 

Ilika will now undertake further optimisation based on the initial test results, before commencing a build and test programme in H2 CY 2025. The Company is targeting an initial release of batteries of this capacity for partner evaluation from the end of CY 2025.

 

Graeme Purdy, CEO of Ilika, said: "This milestone marks the successful conclusion of a grant-funded collaboration, which has enabled Ilika to prototype large EV batteries in readiness for closer engagement with automotive partners. We look forward to securing further support for Goliath commercialisation through the UK government's recent announcement of £2 billion of funding for the electrification of the transport sector."

 

Paul Shearing, Professor of Sustainable Energy Engineering at the Department of Engineering Science and Director of the ZERO Institute at Oxford University, said: "Through the HISTORY programme, Ilika has exemplified what the Faraday Battery Challenge funding was designed to achieve. Through strong collaborations which span industry and academia, this impressive demonstration is a significant milestone in the successful delivery of the programme, which we have been delighted to participate in."

 

Ilika announced in January 2023 receipt of grant support from the Faraday Battery Challenge in a 24-month, £8.2 million 8 partner collaboration programme to integrate high silicon content electrodes into its Goliath solid-state batteries ('SSB') to enable automotive level performance. BMW Group and Fortescue Zero (formerly Williams Advanced Engineering) joined the programme's steering committee.

 

 

ENDS

 

--

Enquiries:

 

Ilika Plc Graeme Purdy, Chief Executive

Jason Stewart, Chief Financial Officer

 

www.ilika.com

Via FTI Consulting

 

Cavendish Capital Markets Limited (Nomad and Broker) Peter Lynch

Neil McDonald

 

+44 (0)131 220 9772

+44 (0)131 220 9771

 

FTI Consulting (Comms Advisors)

Ben Brewerton

Elizabeth Adams

Dwight Burden

ilika@fticonsulting.com

 

 

About Ilika plc - https://www.ilika.com

 

Ilika is a global expert in the development of solid state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDZGGFRKDGKZM
Date   Source Headline
13th May 202410:16 amRNSPosting of Circular & Notice of General Meeting
10th May 20243:02 pmRNSResult of Placing
10th May 20247:00 amRNSProposed Placing and Open Offer & Notice of GM
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.